KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Ratio (2016 - 2025)

Historic Equity Ratio for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to 0.85.

  • CRISPR Therapeutics AG's Equity Ratio fell 74.45% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year decrease of 74.45%. This contributed to the annual value of 0.86 for FY2024, which is 204.68% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Equity Ratio stood at 0.85, which was down 74.45% from 0.84 recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Equity Ratio high stood at 0.92 for Q1 2021, and its period low was 0.83 during Q1 2023.
  • For the 5-year period, CRISPR Therapeutics AG's Equity Ratio averaged around 0.86, with its median value being 0.85 (2022).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Equity Ratio surged by 482.91% in 2021, and later crashed by 676.86% in 2022.
  • CRISPR Therapeutics AG's Equity Ratio (Quarter) stood at 0.87 in 2021, then fell by 4.11% to 0.84 in 2022, then increased by 1.0% to 0.84 in 2023, then increased by 2.05% to 0.86 in 2024, then dropped by 0.98% to 0.85 in 2025.
  • Its Equity Ratio stands at 0.85 for Q3 2025, versus 0.84 for Q2 2025 and 0.84 for Q1 2025.